Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
University of Florida
Rush University Medical Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Children's Oncology Group
Columbia University
University of Cincinnati